2024: RET Therapy for Children

On This Day in Health: May 29, 2024

On May 29, 2024, the U.S. Food and Drug Administration granted accelerated approval to selpercatinib, marketed as Retevmo, for children two years of age and older with qualifying RET-altered cancers. The indications included specified advanced thyroid cancers and certain other advanced solid tumors, with different conditions concerning systemic treatment and earlier therapy. Selpercatinib already had approved uses in older patients. The decision therefore expanded access to younger children rather than introducing a completely new medicine. It was the first FDA approval of a targeted therapy for patients younger than twelve with RET alterations, making the age boundary an essential part of the anniversary.

RET alterations can contribute to cancer growth, but a mutation and a gene fusion are different biological findings. The thyroid indications distinguished RET-mutated medullary thyroid cancer from RET fusion-positive thyroid cancer. The broader solid-tumor indication required a RET fusion and specific circumstances concerning prior treatment or the absence of satisfactory alternatives. Selpercatinib inhibits RET signaling, connecting its design to those tumor features. An organ-based diagnosis alone was not enough to establish the relevant indication. The decision made the test result and the child's clinical situation part of the same treatment discussion, rather than treating all pediatric thyroid cancers or solid tumors as a single group.

Evidence for the younger population came from LIBRETTO-121, an international study of pediatric and young adult patients. Researchers examined tumor responses and how long those responses lasted. The small primary efficacy population included twenty-five participants, a reminder of the challenges involved in studying rare molecularly defined childhood cancers. The results supported accelerated approval while leaving a need for continuing evidence about benefit. Treatment also required attention to adverse effects and clinical monitoring. Bringing an existing targeted medicine into younger age groups involves more than assuming that an adult result applies unchanged. Pediatric studies help connect the formulation, exposure and observed outcomes to the children for whom treatment is being considered.

May 29 highlights the importance of including younger patients in the development of precision cancer care. A biological target may be shared across age groups, yet the route from that observation to a usable pediatric treatment still requires evidence. For families with few satisfactory options, an expanded indication can matter even when the qualifying population is small. The anniversary recognizes the children and young adults who participated in that research and the work of translating their experience into an approval. It also preserves the limits of the decision: defined RET alterations, specified advanced diseases and continuing clinical responsibilities. The achievement widened a carefully bounded opportunity rather than establishing one treatment for every childhood cancer.